Avalo Therapeutics (AVTX) Income from Continuing Operations (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Income from Continuing Operations came in at 19630000.0 in Q1 2026, down 49.29% YoY from 38709488.6 in Q1 2025, and down 43.08% on a QoQ basis from 13720000.0 in Q4 2025.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Income from Continuing Operations data on file, last reported at 19630000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 49.29% year-over-year to 19630000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 84740000.0 (down 216.06% YoY) and the FY2025 annual result came in at 78259000.0, down 122.78% from the prior year.
- Income from Continuing Operations eased to 19630000.0 in Q1 2026, from 13720000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 98463000.0 in Q2 2024 to a low of 121290000.0 in Q1 2024.
- A 5-year average of 12130588.24 and a median of 12987000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 1301.79% in 2024, down 1118.38% in 2024.
- Tracing AVTX's Income from Continuing Operations over 5 years: stood at 9812000.0 in 2022, then grew by 16.75% to 8168000.0 in 2023, then sank by 332.65% to 35339000.0 in 2024, then surged by 61.18% to 13720000.0 in 2025, then plunged by 43.08% to 19630000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 19630000.0 (Q1 2026), 13720000.0 (Q4 2025), and 30625000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Avalo Therapeutics | 838.47 Mn | 838.47 Mn | - | -36.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36.36 Mn |
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | -13.72 Mn |
| Sep 30, 2025 | -30.63 Mn |
| Jun 30, 2025 | -20.77 Mn |
| Mar 31, 2025 | -13.15 Mn |
| Dec 31, 2024 | -35.34 Mn |
| Sep 30, 2024 | 23.04 Mn |
| Jun 30, 2024 | 98.46 Mn |
| Mar 31, 2024 | -121.29 Mn |
| Dec 31, 2023 | -8.17 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | -9.96 Mn |
| Dec 31, 2022 | -9.81 Mn |
| Sep 30, 2022 | 3.19 Mn |
| Jun 30, 2022 | -12.99 Mn |
| Mar 31, 2022 | -22.05 Mn |
| Dec 31, 2021 | -19.15 Mn |
| Sep 30, 2021 | -17.47 Mn |